Postibrutinib Relapse Outcomes for Patients with Marginal Zone Lymphoma

Authors

Narendranath Epperla, The Ohio State University
Qiuhong Zhao, The Ohio State University
Sayan Mullick Chowdhury, The Ohio State University
Lauren Shea, Washington University
Tamara K. Moyo, Levine Cancer Center
Nishitha Reddy, Vanderbilt University Medical Center
Julia Sheets, University of North Carolina
David M. Weiner, University of Pennsylvania
Praveen Ramakrishnan Geethakumari, University of Texas Southwestern Medical Center
Malathi Kandarpa, University of Michigan
Ximena Jordan Bruno, University of Vermont
Colin Thomas, Thomas Jefferson UniversityFollow
Michael C. Churnetski, Emory University Medical Center
Andrew Hsu, Brown University
Luke Zurbriggen, University of Wisconsin
Xiao-Wei Cherie Tan, Cancer Institute of New Jersey
Kathryn Lindsey, Medical University of South Carolina
Joseph Maakaron, University of Minnesota
Paolo F. Caimi, University Hospitals Seidman Cancer Center
Pallawi Torka, Roswell Park Cancer Institute
Celeste Bello, H. Lee Moffitt Cancer Center and Research Institute
Sabarish Ayyappan, University of Iowa
Timothy S. Oh, Northwestern University
Reem Karmali, Northwestern University
Seo-Hyun Kim, Rush University
Anna Kress, Yale University
Shalin Kothari, Yale University
Yazeed Sawalha, The Ohio State University
Beth Christian, The Ohio State University
Kevin A. David, Cancer Institute of New Jersey
Irl Brian Greenwell, Medical University of South Carolina
Murali Janakiram, University of Michigan
Vaishalee P. Kenkre, University of Wisconsin
Adam J. Olszewski, Brown University
Jonathon B. Cohen, Emory University Medical Center
Neil Palmisiano, Thomas Jefferson University
Elvira Umyarova, University of Vermont
Ryan A. Wilcox, University of Michigan
Farrukh T. Awan, University of Texas Southwestern Medical Center
Juan Pablo Alderuccio, University of Miami
Stefan K. Barta, University of Pennsylvania
Natalie S. Grover, University of North Carolina
Nilanjan Ghosh, Levine Cancer Center
Nancy L. Bartlett, Washington University
Alex F. Herrera, Washington University
Geoffrey Shouse, City of Hope Medical Center

Document Type

Letter to the Editor

Publication Date

1-10-2023

Comments

This research letter is the author's final published version in Blood Advances, Volume 7, Issue 1, January 2023, Pg. 88 - 91.

The published version is available at https://doi.org/10.1182/bloodadvances.2022008634. Copyright © 2022 by The American Society of Hematology.

Recommended Citation

Epperla, Narendranath; Zhao, Qiuhong; Chowdhury, Sayan Mullick; Shea, Lauren; Moyo, Tamara K.; Reddy, Nishitha; Sheets, Julia; Weiner, David M.; Geethakumari, Praveen Ramakrishnan; Kandarpa, Malathi; Bruno, Ximena Jordan; Thomas, Colin; Churnetski, Michael C.; Hsu, Andrew; Zurbriggen, Luke; Tan, Xiao-Wei Cherie; Lindsey, Kathryn; Maakaron, Joseph; Caimi, Paolo F.; Torka, Pallawi; Bello, Celeste; Ayyappan, Sabarish; Oh, Timothy S.; Karmali, Reem; Kim, Seo-Hyun; Kress, Anna; Kothari, Shalin; Sawalha, Yazeed; Christian, Beth; David, Kevin A.; Greenwell, Irl Brian; Janakiram, Murali; Kenkre, Vaishalee P.; Olszewski, Adam J.; Cohen, Jonathon B.; Palmisiano, Neil; Umyarova, Elvira; Wilcox, Ryan A.; Awan, Farrukh T.; Alderuccio, Juan Pablo; Barta, Stefan K.; Grover, Natalie S.; Ghosh, Nilanjan; Bartlett, Nancy L.; Herrera, Alex F.; and Shouse, Geoffrey, "Postibrutinib Relapse Outcomes for Patients with Marginal Zone Lymphoma" (2023). Department of Medicine Faculty Papers. Paper 401.
https://jdc.jefferson.edu/medfp/401

Creative Commons License

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.

PubMed ID

36269847

Language

English